Check 35,000+ stocks against 26 valuation models and 37 quality factors

NIOX Group (CSSPF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of NIOX Group $0.86, price $0.90, upside -4.3%, quality 82 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN GB00BJVD3B28

Thin data Sep 24, 2026

NIOX Group

CSSPF · US

Quality WatchlistQuality growthA strong company, but the current price is close to Fair Value.

·Fair value $0.8600 · Fairly valued (−4.3%)

✓Quality 82/100

!Mixed Growth (revenue 5y +15.3 %/yr)

✓Solidly profitable · 14.4% net margin (TTM)

!High debt · generates free cash flow

✓1.8% dividend yield · Sustainable

!Moderate moat 62/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.4000 to bull $1.36 Growth analysisrevenue history, year by year Quality 82/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch NIOX Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.3994 – $0.8989 · fair‑value band $0.4000 – $1.36 · the $0.8989 price screens above the $0.8600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide.

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.

Stock analysis

NIOX Group (CSSPF) currently trades at $0.8989, while our model-based Fair Value estimate is $0.8600, so the stock looks roughly fairly valued today (gap 4.5%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of $0.5200 per share, and 0 of the 22 models we run sit above the $0.8989 price.

Bear case: the Asset-Based group reads lowest at $0.1400, and 22 of the 22 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.4000 (bear) to $1.36 (bull), the price of $0.8989 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 82/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

NIOX Group reported revenue of £48.7M in FY2025 versus £27.9M in FY2021, a compound +14.9%/yr. Reported net income was £7.0M in FY2025, compounding +18.1%/yr from FY2021.

Key figures

Market cap $376M · P/E ratio 44.9 · P/S ratio 6.46 · EPS (TTM) $0.0200 · Dividend yield 1.8% · Net margin 14.4% · Return on equity 11.0% · Return on assets (EBIT) 5.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 20% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −4%, CSSPF screens richer than that median.

Fair Value models

Bear $0.4000 Fair Value $0.8600 Bull $1.36

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0030 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Residual Income $0.1800 $0.1900 $0.2300 76

Growth DCF $0.2000 $0.5900 $1.12 73

FCF DCF $0.2200 $0.5800 $1.36 72

All 24 models by family

DCF Models

FCF DCF $0.2200 $0.5800 $1.36 72

Owner Earnings $0.0700 $0.3600 $0.8500 67

5Y Revenue Exit $0.0900 $0.3700 $0.7600 66

5Y EBITDA Exit $0.1900 $0.5800 $1.10 70

5Y P/E Exit $0.1100 $0.4200 $0.7800 66

10Y Revenue Exit $0.1200 $0.4000 $0.8400 61

10Y EBITDA Exit $0.1900 $0.5500 $1.12 63

10Y P/E Exit $0.1500 $0.4300 $0.8600 59

Earnings-Based

Graham-Dodd $0.1500 $0.8600 $1.19 63

Lynch FV $0.2400 $0.3400 $0.4500 61

PEG = 1.0 $0.2400 $0.3400 $0.4500 57

EPV n/a n/a $0.0200 68

Multiples

P/E Multiple $0.3600 $0.4800 $0.6000 63

P/S Multiple $0.2800 $0.3700 $0.4700 58

P/B Multiple $0.2800 $0.3700 $0.4700 55

EV/EBIT $0.1500 $0.2900 $0.4300 63

EV/EBITDA $0.2100 $0.3700 $0.5300 65

EV/Revenue $0.0200 $0.1500 $0.2900 47

Asset-Based

NCAV (Graham) $0.1100 $0.1400 $0.2100 54

Growth DCF

Growth DCF $0.2000 $0.5900 $1.12 73

Rev-Margin DCF $0.0900 $0.3600 $0.7400 66

Economic Profit

Residual Income $0.1800 $0.1900 $0.2300 76

ROIC Compounder n/a n/a $0.0200 68

Growth Earnings

Growth-Adj P/E $0.3700 $0.5200 $0.6800 67

Open the full fair value analysis →

Notify me when CSSPF reaches fair value

Put CSSPF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 82/100

Of which business quality 80 · Market factors (momentum, volatility) 63

Profitability 58

Margins and returns on capital today

Quality Growth 61

Are margins and returns improving?

Cashflow 98

Earnings quality: real cash, not paper profit

Fin. Strength 81

Balance sheet, leverage, solvency risk

Investment 98

Disciplined investing over empire-building

Low Volatility 94

Calm price path (market factor)

Momentum 40

Price trend over the last 3–12 months (market factor)

52W Momentum 67

Distance to the 52-week high (market factor)

Net Issuance 86

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+16.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.3%

Start year 2020 (pandemic). Over 10 years: +16.3% a year

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.3%

’15

’16

’17

’18

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+16.1%

Earnings growth per share plus dividend.

Earnings per share, growth per year+14.3%

Dividend (yield on the price)1.8%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−72% → 22%

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+20.0%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+6.3%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in GBP, UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +17.3% a year for the price and +3.8% for the forecasts.

Forecast 2026 (sales)+3.4%

Forecast 2027 (sales)+8.1%

Projected 2028 (sales)+7.4%

Projected 2029 (sales)+6.6%

Projected 2030 (sales)+5.8%

Watch CSSPF, get fair value alerts →

Compare NIOX Group with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks

Beats the industry median on 7/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 82 · Top 25%

Fair Value upside −52.4% · Below median

Profitability

Return on equity (TTM) 11.0% · Above median

Return on assets 9.3% · Top 25%

Net margin (TTM) 14.4% · Above median

Operating margin (TTM) 20.9% · Top 25%

Growth and dividend

Revenue growth 20.0% · Top 25%

Dividend yield (TTM) 1.8% · Below median

Balance sheet

Debt / equity 1.63× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 44.9× · Priciest 25%

P/B 4.98× · Priciest 25%

P/S (TTM) 6.91× · Priciest 25%

P/FCF 24.2× · Cheaper than median

EV/EBITDA 29.8× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$98.83	$74.79	−24%
Medtronic plc MDT	$87.09	$65.61	−25%
Stryker Corporation SYK	$278.77	$306.65	+10%
Boston Scientific Corporation BSX	$43.65	$48.02	+10%
Edwards Lifesciences Corporation EW	$85.19	$81.94	−4%
Siemens Healthineers AG SHL	€37.86	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NIOX Group · Fair Value
$0.8600 −4%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CSSPF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">NIOX Group · Fair Value</span><br><b style="font-size:20px">$0.8600</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−4%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "NIOX Group Fair Value". https://www.fairvalue-calculator.com/stock/CSSPF

Frequently asked questions

Is NIOX Group (CSSPF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $0.8600 versus the last price from Sep 25, 2026 of $0.8989, about −4% upside (fairly valued).

What is the fair value of CSSPF?

Our model-based fair value for NIOX Group is $0.8600 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.8989.

What is the quality score of CSSPF?

NIOX Group has a Quality Score of 82/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for NIOX Group (CSSPF)?

Our model-based price target is the fair value of $0.8600 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.4000, optimistic scenario $1.36. It is a calculation from audited fundamentals, not an analyst target.

What is the NIOX Group stock forecast for 2026?

Our models put fair value at $0.8600, about −4% upside versus the last price from Sep 25, 2026 of $0.8989 (fairly valued). Cautious scenario $0.4000, optimistic scenario $1.36. The calculation is refreshed regularly with new filings.

What is the revenue of NIOX Group (CSSPF)?

NIOX Group reported trailing-twelve-month revenue of about £48.7M (latest available figure, as of Sep 24, 2026).

Does NIOX Group pay a dividend?

NIOX Group currently shows a dividend yield of about 1.78% relative to its recent price (as of Sep 24, 2026).

What growth is priced into NIOX Group (CSSPF)?

For today's price to be fair in a discounted-cash-flow model, NIOX Group would have to grow free cash flow by +20.0 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.3 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of CSSPF use?

Our models discount NIOX Group at 11.2 %: a base by market capitalisation (small), country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NIOX Group that is +20.0 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.

How much growth has NIOX Group (CSSPF) delivered so far?

Over the past 5 years revenue at NIOX Group grew +15.3 % a year. The price currently implies +20.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of NIOX Group (CSSPF) growing?

The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into NIOX Group (+20.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of NIOX Group (CSSPF)?

The free-cash-flow yield on the price is 4.90 %: that much free cash flow NIOX Group produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of NIOX Group (CSSPF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NIOX Group it is $0.8600 per share (as of Sep 24, 2026), against a price of $0.8989. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is NIOX Group stock overvalued or undervalued in 2026?

As of Sep 24, 2026, CSSPF trades above its calculated fair value: price $0.8989, fair value $0.8600, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CSSPF?

No. The price is what the market pays today ($0.8989); the fair value is what the company's own numbers justify ($0.8600). For NIOX Group the two are $0.0389 per share apart. That gap is exactly why we show both numbers side by side.

How much is NIOX Group worth?

The market values NIOX Group at about $376M (market capitalisation, as of Sep 24, 2026). Per share that is $0.8989; our models calculate a fair value of $0.8600 per share.

What do the bullish and bearish scenarios say about CSSPF?

Our models span a range for NIOX Group: cautious scenario $0.4000, base $0.8600, optimistic $1.36 per share (as of Sep 24, 2026, price $0.8989). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of CSSPF?

NIOX Group trades at a price-to-earnings ratio of 44.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.8600 is built from several models across several years. Other multiples: P/B 5.0, P/S 6.9, EV/EBITDA 29.8.

How solid is the balance sheet of NIOX Group (CSSPF)?

Balance-sheet figures for NIOX Group (as of Sep 24, 2026): return on equity 11.0%, debt of 1.63 per unit of equity. They feed the Quality Score of 82/100, which measures business quality independently of the share price.

How far is CSSPF from its 52-week high?

NIOX Group trades at $0.8989, at its 52-week high of $0.8989 and 20% above the low of $0.7500 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8600 is for.

Which stocks are comparable to NIOX Group?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is NIOX Group stock attractive at the current price?

The data as of Sep 24, 2026: price $0.8989, calculated fair value $0.8600 (−4%), Quality Score 82/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CSSPF calculated?

We run NIOX Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8600, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. NIOX Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of NIOX Group (CSSPF)?

The latest price we hold is from Sep 25, 2026 and stands at $0.8989. Our model-based fair value is $0.8600, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with NIOX Group right now?

The model range is unusually wide ($0.4000 to $1.36). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NIOX Group

How large is the market capitalisation of NIOX Group (CSSPF)?

The market capitalisation of NIOX Group is $376M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of NIOX Group (CSSPF)?

The price-to-sales ratio of NIOX Group is 6.46 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of NIOX Group (CSSPF)?

Earnings per share at NIOX Group are $0.0200 (price ÷ EPS = P/E 44.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of NIOX Group (CSSPF)?

The dividend yield of NIOX Group is 1.8% (payout 80.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of NIOX Group (CSSPF)?

The net margin of NIOX Group is 14.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of NIOX Group (CSSPF)?

The return on equity (ROE) of NIOX Group is 11.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of NIOX Group (CSSPF)?

On an EBIT basis the return on assets of NIOX Group is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of NIOX Group (CSSPF)?

The operating margin of NIOX Group is 20.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at NIOX Group (CSSPF)?

Revenue at NIOX Group is growing +20.0% versus a year earlier (3y avg +15.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at NIOX Group (CSSPF)?

Earnings per share at NIOX Group are growing +43.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does NIOX Group (CSSPF) carry?

The net debt of NIOX Group is £82.9M (fiscal year 2019, ≈ 6.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch NIOX Group in the live analysis

One click puts NIOX Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.